Entinostat (SNDX-275) for the treatment of non-small cell lung cancer
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Epigenetic aberrations play an important role in lung carcinogenesis. Chromatin deacetylation is a fundamental mechanism of gene silencing. Histone deacetylase (HDAC) inhibitors are an emerging class of antineoplastic agents that enable the accessibility of DNA to transcription factors, therefore promoting gene expression. Entinostat is a selective HDAC inhibitor that has shown anti-neoplastic activity and tolerability in hematologic and solid tumors, including lung cancer. AREAS COVERED: This article summarizes the pharmacokinetics, pharmacodynamics, mechanisms of action, safety, tolerability, pre-clinical studies and clinical trials of the HDAC inhibitor entinostat, as a novel promissory agent for the treatment of NSCLC. EXPERT OPINION: The field of targeted therapy has increased in lung cancer. However, even now with the current FDA-approved agents, < 15% of patients benefit from these interventions and we are still far from curing lung cancer. New targets are needed. Either in combination with cytotoxic drugs, epigenetic therapy or other molecular targeted drugs, entinostat represents a new potential agent for the treatment of non-small cell carcinomas. However, the preliminary safety and efficacy results from several clinical trials still need to be validated in large Phase III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · cited 1×
“Molecular targeted therapy has importantly improved progression-free survival (PFS) in patients with specific genetic mutations [6-9].”
BackgroundSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · cited 3×
“1 Chemistry, pharmacokinetics and metabolism Entinostat, previously known as SNDX-275 and MS-275 (Box 1) is a synthetic benzamide derivative [25] that inhibits only the class I enzymes HDAC1 to HDAC3 [16].”
BackgroundDuvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141 · cited 1×
“Two of them, vorinostat (hydroxamic acid class) and romidepsin (cyclic tetrapeptide), have demonstrated antitumor activity in the treatment of cutaneous T-cell lymphoma and are currently FDA approved [20-23].”
BackgroundYauch, R. L., Januario, T., Eberhard, D. A., Cavet, G., Zhu, W., Fu, L., Pham, T. Q., Soriano, R., Stinson, J., Seshagiri, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1492 · Cited by 495
Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171 · cited 5×
“Entinostat inhibition of HDAC has been determined through the analysis of histones H3 and H4 acetylation status in peripheral blood or bone marrow mononuclear cells, either through immunohistochemistry (IHC) [27-29] or flow cytometry [30].”
BackgroundMethodInfluentialEntinostat for treatment of solid tumors and hematologic malignancies
Knipstein, J., & Gore, L. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.613822 · Cited by 110 · cited 2×
“Furthermore, in vivo antitumor activity has been demonstrated in human tumor models [31,34].”
Background
Cited by
The role of protein acetylation in carcinogenesis and targeted drug discovery
Yang, J., Song, C., & Zhan, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972312 · Cited by 42
Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050336 · Cited by 28
HDAC1 governs iron homeostasis independent of histone deacetylation in iron-overload murine models
Yin, X., Wu, Q., Monga, J., Xie, E., Wang, H., Wang, S., Zhang, H., Wang, Z.-Y., Zhou, T., Shi, Y., et al. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7161 · Cited by 22
“Moreover, entinostat has a well-characterized safety profile due to its high selectivity for inhibiting HDAC1 (38).”
Metadata
- Authors
- Ruiz, R., Raez, L. E., & Rolfo, C.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2015-06-22
- Volume
- 24
- Issue
- 8
- Pages
- 1101-1109
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1852761976
- Cited by
- 43
- References
- 8
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. https://app.cochat.ai/papers/10.1517/13543784.2015.1056779
- The paper
- Ruiz, R., Raez, L. E., & Rolfo, C. (2015). Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.2015.1056779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.